Attached files
file | filename |
---|---|
EX-31.1 - EXHIBIT 31.1 - KalVista Pharmaceuticals, Inc. | d914057dex311.htm |
EX-31.2 - EXHIBIT 31.2 - KalVista Pharmaceuticals, Inc. | d914057dex312.htm |
EXCEL - IDEA: XBRL DOCUMENT - KalVista Pharmaceuticals, Inc. | Financial_Report.xls |
10-Q - FORM 10-Q - KalVista Pharmaceuticals, Inc. | d914057d10q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO SECTION 906 OF
THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)
In connection with the accompanying Quarterly Report of Carbylan Therapeutics, Inc. (the Company) on Form 10-Q for the fiscal quarter ended March 31, 2015 (the Report), I, David M. Renzi, as President and Chief Executive Officer of the Company, and T. Michael White, as Chief Financial Officer and Vice President, Finance of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: May 21, 2015 | /s/ David M. Renzi | |
David M. Renzi | ||
President and Chief Executive Officer | ||
Dated: May 21, 2015 | /s/ T. Michael White | |
T. Michael White Chief Financial Officer and Vice President, Finance |